Osteogenic Potential of Human Bone Marrow Cells

Information

  • Research Project
  • 6930935
  • ApplicationId
    6930935
  • Core Project Number
    R01DK061456
  • Full Project Number
    5R01DK061456-03
  • Serial Number
    61456
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/2003 - 22 years ago
  • Project End Date
    12/31/2007 - 17 years ago
  • Program Officer Name
    BISHOP, TERRY ROGERS
  • Budget Start Date
    1/1/2005 - 20 years ago
  • Budget End Date
    12/31/2005 - 19 years ago
  • Fiscal Year
    2005
  • Support Year
    3
  • Suffix
  • Award Notice Date
    12/27/2004 - 20 years ago

Osteogenic Potential of Human Bone Marrow Cells

DESCRIPTION (provided by applicant): This proposal seeks to understand the nature and degree to which human stem cells can form cells of the osteogenic lineage. The central hypothesis is that expression of osteogenic potential resides within a single population of multipotent stem cells that phenotypically differs depending upon its locale. We will test this hypothesis by examining three populations of cells reported to have osteogenic potential: bone marrow hematopoietic cells (focusing on CD34-negative cells), mesenchymal stem cells, and a recently described population of human bone precursor cells. The first goal of this proposal is to determine whether these populations of Osteopoietic Stem Cells (OSC) are related. This is accomplished by viral based marking studies and in vitro evaluation of the osteogenic potential of these cells. We have developed isolation and purification protocols that allow us to examine the function of osteoprogenitor cells, preosteoblasts, and osteoblast. The viral marking studies will utilize both lenti- and retroviral mediated gene transfer of GFP, taking care to deplete the three populations of more mature cells via lineage-depletion. Using our clonal osteoprogenitor cell assay, we take an alternative approach in which GFP-positive OPC from each population of virally marked cells are analyzed for integration by inverse-PCR. As well, a Power-Analysis of large numbers of marked OPC will be use to overcome problems of OSC frequency, integration efficiency, and signal-dilution. The second aim is to examine if the osteogenic fate of OSC populations can be enhanced. Such fate decisions are hypothesized to be modulated via manipulation of cell-intrinsic and/or cell-extrinsic mechanisms. Intrinsic mechanisms are investigated by modulation of bone related transcription factors (e.g., Fral, delta-fos B and others) and evaluation of their affect on osteogenic commitment and ex vivo bone formation. Extrinsic control of osteogenic fate determine focuses on the role of an accessory cell population, recently identified in this laboratory, as well as enforced expression of bone-active cytokines by CHO cells that function as "artificial Stromal cells." The final set of experiments focuses on the fate of OSC populations in vivo. These studies will determine the degree to which OSC can "home" to the osteogenic microenvironment in immuno-compromised Nude/NOD/SCID mice. As well, we will explore the capacity of these cells to commit to the osteogenic lineage and restore bone formation in osteoporotic NOD/SCID mice, as well as mice with skeletal defects.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    363000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    849
  • Ed Inst. Type
  • Funding ICs
    NIDDK:363000\
  • Funding Mechanism
  • Study Section
    HEM
  • Study Section Name
    Hematology Subcommittee 2
  • Organization Name
    VELCURA THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    117950324
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481085010
  • Organization District
    UNITED STATES